| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/01/2008 | US20080102071 T cell inhibitory receptor compositions and uses thereof |
| 05/01/2008 | US20080102064 Mixture comprising blood coagulation factor and serpin for use in prevention and treatment of blood disorders |
| 05/01/2008 | US20080102060 Methods of using bcl-2 for the therapeutic treatment and prevention of diseases |
| 05/01/2008 | US20080102055 Method for detecting Alzheimer's disease |
| 05/01/2008 | US20080102034 Antihyperplastic agent preparation applicable to angiography catheter; enhancing artery and/or vein imaging; side effect reduction; rapid, efficient absorption through capillary walls |
| 05/01/2008 | US20080102033 Antihyperplastic agent preparation applicable to angiography catheter; enhancing artery and/or vein imaging; side effect reduction; rapid, efficient absorption through capillary walls |
| 04/30/2008 | EP1916307A1 Plant enzymes for bioconversion |
| 04/30/2008 | EP1916301A1 Method for evaluating compound using molecule on the rb pathway as index and molecular diagnostic method |
| 04/30/2008 | EP1916001A2 Human antibodies specific to KDR and uses thereof |
| 04/30/2008 | EP1915994A1 Cyclic amine derivative containing ppar regulator |
| 04/30/2008 | EP1915993A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 04/30/2008 | EP1915992A1 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
| 04/30/2008 | EP1601664B1 Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders |
| 04/30/2008 | EP1531805B1 Composition devoid of ascorbic acid comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 04/30/2008 | EP1372677B1 Use of compositions comprising sesquiterpene derivatives for the treatment of cancer |
| 04/30/2008 | EP1307486B1 Somatostatin analogues |
| 04/30/2008 | EP1212417B1 Promotion or inhibition of angiogenesis and cardiovascularization |
| 04/30/2008 | EP1196156B1 Transnasal anticonvulsive compositions |
| 04/30/2008 | EP0981360B1 Method for preventing gastritis using amylin or amylin agonists |
| 04/30/2008 | DE202007011825U1 Pharmazeutische Dosierungsformen Pharmaceutical dosage forms |
| 04/30/2008 | DE112005002530T5 Neue Verfahren für die in-vitro Identifikation, Isolierung und Differenzierung von vaskulogenischen Vorläuferzellen New method for the in vitro identification, isolation and differentiation of vasculogenic progenitor cells |
| 04/30/2008 | CN101171038A The use of free radical scavengers for protecting and treating skin and hair damages caused by chemotherapy |
| 04/30/2008 | CN101171036A Delivery of TIGECYCLINE in the presence of WARFARIN |
| 04/30/2008 | CN101171010A Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| 04/30/2008 | CN101168062A Double-shell medicine sustained and controlled releasing carrier material and preparation method and application thereof |
| 04/30/2008 | CN101168061A Biological degradable polymer-solid liposome sustained-release storing system and preparation method thereof |
| 04/30/2008 | CN101168060A Stable medicinal composition containing biguanide and sulfonylurea and preparation method thereof |
| 04/30/2008 | CN101168059A Stable medicinal composition containing biguanide, sulfonylurea and thiazolidinedione and preparation method thereof |
| 04/30/2008 | CN101168058A Mixture preparation |
| 04/30/2008 | CN101168057A Dopamine agonist preparation |
| 04/30/2008 | CN101168056A 混合物制剂 Mixture preparation |
| 04/30/2008 | CN100384837C Novel farnesyl protein transferase inhibitors as antitumor |
| 04/30/2008 | CN100384482C Method of examining effect of angiogenesis inhibitors mediated by the inhibition of integrin expression |
| 04/30/2008 | CN100384476C Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
| 04/30/2008 | CN100384474C Skin immune function controlling agents |
| 04/30/2008 | CN100384468C L-methionine as a stabilizer for NESP/EPO in hsa-free formulations |
| 04/30/2008 | CN100384430C Combination therepy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| 04/30/2008 | CN100384424C Synergistic methods and compositions for treating cancer |
| 04/30/2008 | CN100384423C Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 04/30/2008 | CN100384422C Anti-microbial composition comprising a metal ion chelating agent |
| 04/30/2008 | CN100384412C Methods and compositions for inhibiting 5 'alpha'-reductase activity |
| 04/30/2008 | CN100384409C Use of triethylene-tetramine as antitumour auxiliary drug |
| 04/29/2008 | US7365221 Viricides; aids therapy |
| 04/29/2008 | US7365169 T-bet antibodies |
| 04/29/2008 | US7365054 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| 04/29/2008 | US7364867 Nucleotide sequences which code a membrane protein for use in flavor intensification of in food, beverages or pharmaceuticals |
| 04/29/2008 | US7364864 ANGE gene in atopy |
| 04/29/2008 | US7364852 Using presence of short expansion sequences in poly(A) binding protein II (PAB II) gene as diagnostic indicator of disease associated with polyalanine and protein accumulation in nucleus |
| 04/29/2008 | US7364847 nucleic acid that binds to high mobility group protein-I (HMG-I), and causes presenilin-2 gene exon 5-lacked type aberrant splicing by the association with the HMG-I protein; an inhibitor for inhibiting a binding between protein-nucleic acid caused by aberrant splicing; drug screening; antisense agents |
| 04/29/2008 | US7364736 Immmunoglobulin which prevents binding of osteoprotegerin ligand (OPGL) to osteoclast differentiation and activation receptor (ODAR) for treatment and prevention of bone, inflammatory, arthritic and autoimmune disorders |
| 04/29/2008 | US7364722 Pharmaceutical and cosmetic compositions comprising plgf-1 |
| 04/29/2008 | CA2416492C Treatment of glycogen storage disease type ii |
| 04/29/2008 | CA2406798C Pharmaceutical parenteral composition containing a biphosphonate |
| 04/29/2008 | CA2370098C Human beta-trcp protein |
| 04/29/2008 | CA2343204C Arylsulfonanilide ureas |
| 04/29/2008 | CA2312990C Novel salts of metformin and method |
| 04/29/2008 | CA2309178C Topical compositions for nsai drug delivery |
| 04/29/2008 | CA2304712C Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
| 04/29/2008 | CA2294756C Cross-linked polysaccharide drug carrier |
| 04/29/2008 | CA2259960C Down-regulation of dna repair to enhance sensitivity to p53-mediated suppression |
| 04/29/2008 | CA2244078C Use of leukotriene b4 or its analogues as antiviral and antineoplastic agents |
| 04/28/2008 | CA2666796A1 Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders |
| 04/24/2008 | WO2008047574A1 Sensitizer for anticancer agent |
| 04/24/2008 | WO2008047486A1 Myocardial injury-controlling agent |
| 04/24/2008 | WO2008047365A1 Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders |
| 04/24/2008 | WO2008047364A2 Method and pharmacological composition for the diagnosis and treatment of male sub-fertility |
| 04/24/2008 | WO2008047340A1 Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders |
| 04/24/2008 | WO2008046882A2 Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss |
| 04/24/2008 | WO2008046860A2 Bioavailable combinations for hcv treatment |
| 04/24/2008 | WO2008046857A1 Long-term enteral feed for maintenance |
| 04/24/2008 | WO2008014299A3 Use of an alpha2-agonist composition for the treatment of hyperlipidemia |
| 04/24/2008 | WO2007149285A3 Method of improved diuresis in individuals with impaired renal function |
| 04/24/2008 | WO2007144082A3 Combination antihypertensive wafer |
| 04/24/2008 | WO2007144080A3 Combination antidepressants wafer |
| 04/24/2008 | WO2007011874A3 Formulation and method for administration of ophthalmologically active agents |
| 04/24/2008 | US20080097082 Nucleotide sequences coding recombinant protein for use in prevention and treatment of hyperphosphatemia |
| 04/24/2008 | US20080096981 modulating activities associated with the IL-9 pathway for the treatment of atopic allergies like asthma; autoimmune diseases; new genes tightly expressed in association with an inflammatory response in the airways mediated by type 2 helper T-cells (TH). These genes have been designated TH2AF1 |
| 04/24/2008 | US20080096952 Methods for the treatment of atherosclerosis, using substituted phenethylsulfones |
| 04/24/2008 | US20080096948 Serotonin antagonist compositions and methods for the local inhibition of pain and inflammation |
| 04/24/2008 | US20080096890 Highly Selective Norepinephrine Reuptake Inhibitors and Methods of Using the Same |
| 04/24/2008 | US20080096865 Improved photodynamic treatment against subfoveal choroidal neovascularization; administering midostaurin, vatalanib dihydrochloride or octreotide with a photosensitive porphyrin or purpurin; angiogenesis inhibition |
| 04/24/2008 | US20080096864 Partially imatinib-resistant tumors; synergistic; combined packaging; oral administration |
| 04/24/2008 | US20080096854 Orally administering edible oil homogenized with edible wax and a sterol comprising stigmasterol, campesterol, p-sitosterol, chalinosterol, clionasterol, brassicasterol, alpha -spinasterol, daucosterol, desmosterol, and poriferasterol to treat colorectal, stomach, and/or esophagus cancer |
| 04/24/2008 | US20080096802 administering peroxisome proliferator-activated receptor agonists (PPAR) and sodium glucose co-transporters (SGLTs) inhibitors for the treatment of diabetes and Syndrome X |
| 04/24/2008 | US20080096250 Expression vector comprising nucleotide sequences coding inflammatory response polypeptide for use in treatment and prevention of inflammation |
| 04/24/2008 | US20080095854 Ballast administering to mammals skins; high density core overcoated with amorphous reservoir containing dna; drug delivery; containing free radical scavenger |
| 04/24/2008 | US20080095851 Phospholipid-free, having a D50 particle size of less than 500 nm, and having a surface stabilizer; improved pharmacokinetic profiles and reduced fed/fasted variability |
| 04/24/2008 | US20080095823 Stent grafts; sutures; biodegradable |
| 04/24/2008 | US20080095793 Expression vector comprising nucleotide sequences coding protein fusion for use in treatment and prevention of microorganismal infection |
| 04/24/2008 | US20080095778 Treatment Of Fungal Infections |
| 04/24/2008 | US20080095773 Polypeptides homologous to vegf and bmp1 |
| 04/24/2008 | DE102006049585A1 Nail varnish useful for treating toenail and fingernail disorders comprises urea; fatty acids; allantoin, dexpanthenol, hyaluronic acid, penetration enhancer, antimicrobial agent, antipsoriatic agent and/or antieczema agent |
| 04/24/2008 | DE102006049527A1 Use of potassium voltage channel 1.5 inhibitors for producing a medicament for the therapy or prophylaxis of e.g. respiratory disorders, upper airway resistance syndrome, neurodegenerative disorders and lung cancer |
| 04/24/2008 | CA2666794A1 Method and pharmacological composition for the diagnosis and treatment of male sub-fertility |
| 04/24/2008 | CA2666765A1 Novel use |
| 04/23/2008 | EP1913952A1 Molecular determinants of myeloma bone disease and uses thereof |
| 04/23/2008 | EP1913948A1 Re-epithelializing pharmaceutical compositions containing xanthan gum |
| 04/23/2008 | EP1913944A1 Pharmaceutical combinations and their use in treating gastrointestinal disorders |
| 04/23/2008 | EP1913155A1 Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy |
| 04/23/2008 | EP1912658A1 Therapeutic protocols using hyaluronan |